K
Katherine P. Sugarman
Researcher at Eli Lilly and Company
Publications - 11
Citations - 5114
Katherine P. Sugarman is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Pemetrexed & Gemcitabine. The author has an hindex of 7, co-authored 10 publications receiving 4899 citations.
Papers
More filters
Journal ArticleDOI
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
TL;DR: This is the first prospective phase III study in NSCLC to show survival differences based on histologic type and cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cis platin/gemcitabine.
Journal ArticleDOI
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu,Thomas Brodowicz,Christoph C. Zielinski,Joo Hang Kim,Maciej Krzakowski,E. Laack,Yi-Long Wu,Isabel Bover,Stephen Begbie,Valentina Tzekova,Branka Cucevic,José Rodrigues Pereira,Sung Hyun Yang,Jayaprakash Madhavan,Katherine P. Sugarman,Patrick Peterson,William J. John,K. Krejcy,Chandra P. Belani +18 more
TL;DR: Maintenance therapy with pemetrexed is well tolerated and offers improved progression-free and overall survival compared with placebo in patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Giorgio V. Scagliotti,Nasser H. Hanna,Frank V. Fossella,Katherine P. Sugarman,J. Blatter,Patrick Peterson,Lorinda Simms,Frances A. Shepherd +7 more
TL;DR: It is suggested pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, it may be preferable to other agents for treatment of patients with nonsquamous NSCLC.
Journal ArticleDOI
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Giorgio V. Scagliotti,Thomas Brodowicz,Frances A. Shepherd,Christoph C. Zielinski,Johan Vansteenkiste,Christian Manegold,Lorinda Simms,Frank V. Fossella,Frank V. Fossella,Katherine P. Sugarman,Chandra P. Belani +10 more
TL;DR: These analyses demonstrate a statistically significant interaction between treatment effect and NSCLC histology, indicating superior efficacy of pemetrexed in nonsquamous patients compared with other standard treatment options.
Journal ArticleDOI
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Kostas N. Syrigos,Johan Vansteenkiste,Purvish M. Parikh,J. von Pawel,Christian Manegold,Renato G. Martins,Lorinda Simms,Katherine P. Sugarman,Carla Visseren-Grul,G.V. Scagliotti +9 more
TL;DR: NSCLC histology significantly predicts efficacy outcomes for patients receiving pemetrexed and several other factors are prognostic for the overall study population as well as a subset of patients with advanced nonsquamous NSCLC.